Lys Therapeutics awarded $5m to advance neuro pipeline
French biotech Lys Therapeutics has received a grant award of $5 million (£3.6 million) from The Michael J Fox Foundation for Parkinson’s Research (MJFF) to accelerate the clinical development of its first-in-class monoclonal antibody for the treatment of Parkinson’s disease and other neurodegenerative disorders.
The funding will go towards the development of the company’s LYS241 monoclonal antibody which is designed to neutralise the pathological mechanisms associated with blood-brain barrier (BBB) dysfunction. Impairment of the BBB can promote the entry of toxic molecules and inflammatory cells into the central nervous system, leading to neuroinflammation, excitotoxicity, and neuronal death.
Lys Therapeutics states that its approach to LYS241 and Parkinson’s and other neurological disorders is to tackle the fundamental cause of disease progression, rather than limiting treatment to symptom control. As such, LYS241 is designed to block the interaction between tissue plasminogen activator (tPA) and the NMDA receptor (NMDAr) in the vascular compartment — a key driver of BBB dysfunction, neuroinflammation, and dopaminergic neuron degeneration in Parkinson’s disease.
While other therapeutic approaches must cross the BBB to reach their target, LYS241 is designed to work from within the blood vessels. By restoring vascular NMDA receptor function Lys Therapeutics hopes that LYS241 can re-establish BBB integrity, halt the infiltration of harmful immune cells into the brain, and interrupts a cascade of events leading to neurodegeneration
The new funding is part of MJFF’s Therapeutic Pipeline Program and will support the completion of preclinical development and the launch of first-in-human clinical trials for LYS241
“We are honoured by the continued trust of The Michael J Fox Foundation. This grant is both a strong validation of the science behind LYS241 and a powerful catalyst for our development programme. It enables us to move with confidence toward clinical evaluation, with the goal of offering patients a truly novel therapeutic option.” said Dr Manuel Blanc, CEO and Co-founder of Lys Therapeutics.
“Our collaborative work with Lys Therapeutics and INSERM in France has shown that the tPA–NMDAr interaction plays a central role in Parkinson’s pathology. By blocking this mechanism, LYS241 targets a root cause of disease progression rather than simply managing symptoms — representing a true paradigm shift,” said Professor Daniel Lawrence, Department of Internal Medicine and Department of Molecular & Integrative Physiology at the University of Michigan, USA.
“The Michael J Fox Foundation continues its pursuit toward our singular and urgent mission of delivering improved therapies and a cure for patients living with Parkinson’s disease,” said Dr Jessica Tome Garcia, MJFF’s lead scientific programme manager. “This work with Lys Therapeutics on a novel approach targeting neuroinflammation is an example of the field’s robust pipeline of new class treatments that goes beyond symptom management by targeting the underlying disease biology.”
